Lumateperone

Introduction Overview

Generic Name

lumateperone

Brand Name

Caplyta

Dosage Form

oral capsule (10.5 mg, 21 mg, 42 mg)

Drug Class

Atypical antipsychotics

Pharmacokinetics

Absorption:
Lumateperone is well absorbed following oral administration, with peak plasma concentrations typically reached within 1–2 hours post-dose. The absorption is not significantly affected by food intake, allowing flexible dosing with or without meals. Clinical pharmacokinetic studies have demonstrated important variability among patients, but overall oral bioavailability remains adequate for therapeutic effect. The rapid absorption correlates with early onset of action observed in schizophrenia patients as soon as one week after treatment initiation.

Distribution:
Lumateperone exhibits extensive distribution throughout body tissues, including central nervous system penetration, essential for its therapeutic effects on schizophrenia and bipolar depression. The drug is highly lipophilic, facilitating blood-brain barrier crossing. Plasma protein binding of lumateperone is moderate to high, which influences its free drug concentration and distribution volume. Lumateperone's volume of distribution (Vd) suggests wide tissue distribution, supporting its activity in multiple neurotransmitter systems.

Metabolism:
Lumateperone undergoes complex and extensive metabolism primarily via oxidative pathways mediated by cytochrome P450 enzymes, including CYP3A4, CYP1A2, and CYP2C8 isoforms. Several metabolites are formed, predominantly inactive, but some may have minor pharmacologic activity. The drug is also subject to glucuronidation and other phase II metabolic reactions facilitating excretion. Metabolic pathways influence lumateperone’s plasma half-life and potential drug interactions. Liver function significantly impacts metabolism, requiring dosage adjustments in moderate to severe hepatic impairment.

Elimination:
The elimination of lumateperone and its metabolites occurs predominantly via renal excretion, with fecal elimination as a secondary route. The terminal half-life is approximately 18 hours, supporting once-daily dosing. Renal clearance is an important consideration, although no significant dose adjustment is recommended solely based on renal impairment. Steady-state plasma concentrations are generally achieved within 5-7 days of repeated dosing, aligning with clinical observations of symptom improvement.

Dosage Forms

Available Dosage Forms:
- Oral capsule: 10.5 mg, 21 mg, and 42 mg strengths.

Dosages for Adults and Adolescents:
- Schizophrenia: 42 mg orally once daily.
- Bipolar 1 or 2 disorder (depression associated): 42 mg orally once daily, can be used as monotherapy or adjunctively with lithium or valproate.

Specific Patient Populations:
- In patients with moderate to severe hepatic impairment, dosage reduction to 21 mg once daily is recommended due to altered metabolism and clearance.
- Use in geriatric patients requires caution due to increased risk of adverse effects, especially in dementia-related psychosis where Caplyta is contraindicated.
- Safety and efficacy in pediatric populations have not been established; thus, use is restricted to adults.
- No specific dosage adjustment is generally required for patients with renal impairment, though monitoring is advisable.

Clinical Guidelines:
- Capsules should be taken once daily, at the same time each day, with or without food.
- Evening dosing may mitigate sedation and somnolence adverse effects.
- Adherence to prescribed dosing is critical for optimal therapeutic effect and minimizing risks.

Mechanism Of Action

Lumateperone, the active ingredient in Caplyta, is an atypical antipsychotic agent whose mechanism of action involves modulation of multiple neurotransmitter systems in the brain, which are implicated in psychiatric disorders such as schizophrenia and bipolar depression. Its primary molecular effect is mediated through potent antagonist activity at dopamine D2 receptors, which helps to reduce psychotic symptoms like hallucinations and delusions by modulating dopaminergic signaling in the mesolimbic pathway.

In addition to D2 receptor antagonism, lumateperone exhibits significant affinity for serotonin receptors, particularly as a serotonin 5-HT2A receptor antagonist. This serotonin receptor modulation contributes to an improved side effect profile relative to typical antipsychotics and may influence mood regulation pathways relevant to bipolar depression. The combined dopamine and serotonin receptor activities create a balanced neurotransmitter effect that alleviates both positive and negative symptoms of schizophrenia.

Further, lumateperone influences glutamatergic neurotransmission. It has been shown to indirectly modulate glutamate signaling through its effects on NMDA receptor function and calcium-dependent signaling pathways, which may enhance synaptic plasticity and cognitive functions impaired in schizophrenia. This glutamatergic interaction distinguishes lumateperone from some other antipsychotics and supports its efficacy in mood disorders.

Clinically, this multimodal neurotransmitter modulation translates into improved symptom control with a lower incidence of extrapyramidal symptoms and weight gain compared to other atypical antipsychotics. The relatively novel pharmacodynamic profile is supported by clinical trials demonstrating rapid improvement in schizophrenia symptoms as measured by PANSS scores and beneficial effects in bipolar depression. Comparative studies suggest lumateperone’s distinct receptor binding profile contributes to a favorable safety and tolerability profile.

Pharmacological Actions

Antagonism of dopamine D2 receptors reducing psychotic symptoms.
Antagonism of serotonin 5-HT2A receptors improving mood and psychotic symptom balance.
Modulation of glutamatergic neurotransmission enhancing cognitive and mood regulation.
Rapid onset of action in reducing positive and negative schizophrenia symptoms.
Reduction of depressive symptoms in bipolar disorder as monotherapy or adjunctive therapy.
Minimal effects on histaminergic and muscarinic receptors, lowering sedation and anticholinergic side effects.
Low propensity to induce weight gain compared to other atypical antipsychotics.
Improvement in overall neurochemical balance of dopamine, serotonin, and glutamate pathways.
Favorable effect on extrapyramidal symptoms with low incidence of tardive dyskinesia.
Potential pro-cognitive effects through modulation of neurotransmitter systems.
Overall atypical antipsychotic profile with distinct receptor binding properties.
Therapeutic effects on mood stabilization via serotonergic and dopaminergic modulation.
Moderate plasma protein binding influencing steady-state pharmacodynamics.
Metabolic profile showing limited adverse metabolic effects such as glucose dysregulation.

Therapeutic Or Clinical Uses

Treatment of schizophrenia in adult patients to manage positive and negative symptoms.
Management of depressive episodes associated with bipolar 1 disorder in adults.
Management of depressive episodes associated with bipolar 2 disorder in adults.
Monotherapy for bipolar depression or adjunctive therapy with lithium or valproic acid.
Potential reduction of psychosis-related behavioral disturbances.
Alleviation of hallucinations, delusions, and disorganized thinking.
Improvement in mood symptoms including low mood and depressive affect.
Use in patients who require atypical antipsychotic therapy with minimal metabolic side effects.
Therapeutic option for patients intolerant to other antipsychotic medications.
Symptom control in adults with severe mental illness requiring once-daily oral dosing.
Avoidance of exacerbation of extrapyramidal symptoms compared to typical antipsychotics.
Treatment option for patients with coexisting mood and psychotic symptoms.
Part of comprehensive management plan including psychotherapy and lifestyle modifications.
Off-label consideration for other psychiatric disorders under clinical evaluation.
Use in patients with a history of treatment resistance to other antipsychotic agents.

Side Or Adverse Effects

Common side effects include sleepiness (somnolence).
Dizziness, which may be related to orthostatic hypotension.
Nausea as a gastrointestinal adverse event.
Dry mouth (xerostomia) reported frequently.
Potential for fertility problems in both males and females.
Serious risk of increased mortality in elderly patients with dementia-related psychosis.
Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults.
Possibility of cerebrovascular adverse events including stroke in elderly patients.
Neuroleptic malignant syndrome (NMS), a rare but life-threatening condition.
Tardive dyskinesia: uncontrolled facial or body movements, possibly irreversible.
Metabolic disturbances: hyperglycemia and new or worsening diabetes mellitus.
Elevated cholesterol and triglyceride levels requiring monitoring.
Weight gain, although less commonly reported with Caplyta compared to other antipsychotics.
Low white blood cell count (leukopenia), necessitating blood monitoring.
Orthostatic hypotension leading to falls, fractures, and injuries.
Seizure risk increased in susceptible individuals.
Difficulty swallowing (dysphagia) that may lead to aspiration.
Impaired thermoregulation causing inability to adequately control body temperature.
Allergic reactions including rash, hives, and anaphylaxis in rare cases.

Precautions

Avoid use in elderly patients with dementia-related psychosis due to increased mortality risk.
Monitor for emergent suicidal ideation and behavior, especially during early treatment phases.
Regular blood glucose monitoring in patients with diabetes or risk factors for hyperglycemia.
Lipid profile assessments at baseline and periodically during therapy.
Dose adjustment necessary in patients with moderate to severe hepatic impairment.
Caution in patients with a history of seizures or conditions lowering seizure threshold.
Monitor blood pressure to detect orthostatic hypotension and prevent falls.
Beware of sedation and drowsiness impacting driving or operating machinery.
Assess for signs of neuroleptic malignant syndrome promptly when symptoms arise.
Monitor white blood cell counts to detect leukopenia or neutropenia.
Evaluate swallowing ability to reduce aspiration risk.
Use caution in patients with cardiovascular diseases or history of stroke.
Consider fertility implications and discuss reproductive planning with patients.
Pregnancy risk counseling regarding fetal harm and neonatal withdrawal phenomena.
Advise patients on careful hydration and avoidance of overheating or dehydration.

Warnings

Boxed Warning: Increased risk of death in elderly patients with dementia-related psychosis.
Boxed Warning: Increased risk of suicidal ideation and behavior in children, adolescents, and young adults.
Risk of stroke and other cerebrovascular adverse events in elderly with dementia.
Potential for neuroleptic malignant syndrome, a life-threatening neurological emergency.
Possibility of irreversible tardive dyskinesia after drug discontinuation.
Metabolic syndrome components including hyperglycemia, weight gain, and lipid abnormalities.
Orthostatic hypotension causing syncope and falls, especially in the elderly.
Seizure risk potentiation requiring cautious use in at-risk populations.
Risk of dysphagia and aspiration pneumonia.
Impaired thermoregulation potentially resulting in hyperthermia.
Potential drug allergy or hypersensitivity reactions necessitating emergency intervention.
CNS depression leading to sedation, somnolence, and psychomotor impairment.
Avoid abrupt discontinuation to prevent symptom exacerbation or withdrawal.
Use caution with concomitant CNS depressants to prevent additive sedation.
Increased monitoring required when used concomitantly with other psychotropic medications.

Contraindication

Known hypersensitivity to lumateperone or any capsule excipients.
Use in elderly patients with dementia-related psychosis due to increased mortality risk.
History of neuroleptic malignant syndrome related to lumateperone or other antipsychotics.
Concurrent use with drugs known to prolong QT interval in patients at high risk of arrhythmias.
Severe hepatic impairment when dose adjustments cannot be ensured.
Patients with lowered seizure threshold not adequately controlled or monitored.
Known allergy to capsule colorants such as FD& C blue #1, red #3, or iron oxides if sensitivity is confirmed.
Use during pregnancy unless benefits outweigh risks, especially in last trimester.
Concomitant use of drugs with strong CYP3A4 inhibitors without dose adjustment.
Breastfeeding contraindicated without careful risk-benefit assessment.

Drug Interactions

CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) may increase lumateperone plasma levels.
CYP3A4 inducers (e.g., carbamazepine, rifampin) may reduce lumateperone efficacy.
Concomitant use with CNS depressants (benzodiazepines, opioids) can enhance sedation and respiratory depression.
Use with anticholinergic medications may increase risk of dry mouth and cognitive impairment.
Drugs that prolong QT interval may increase risk of cardiac arrhythmias when combined with Caplyta.
Use with antihypertensive agents may potentiate orthostatic hypotension.
Interaction with seizure medications may require dose adjustments and careful monitoring.
Co-administration with lithium or valproic acid is common in bipolar disorder but necessitates monitoring for additive CNS effects.
Caution with certain antibiotics, antifungals, and antivirals affecting CYP enzyme activity.
Concurrent use of St. John's wort may decrease lumateperone effectiveness by inducing metabolism.
Interactions with bronchodilators or asthma medications may exacerbate side effects.
Cold or allergy medicines (e.g., diphenhydramine) may enhance sedation.
Anti-Parkinson drugs may alter psychotropic response to lumateperone.
Medications for overactive bladder or irritable bowel syndrome may interact via anticholinergic pathways.
Herbal supplements and vitamins should be disclosed to healthcare providers to avoid unanticipated interactions.

Preparations Of The Drug

Caplyta oral capsules containing lumateperone at 10.5 mg strength.
Caplyta oral capsules containing lumateperone at 21 mg strength.
Caplyta oral capsules containing lumateperone at 42 mg strength.
Inactive ingredients include croscarmellose sodium, gelatin, magnesium stearate, mannitol, and talc.
Colorants vary by capsule strength: FD&C blue #1 and red #3 for 42 mg; FDA/E172 black and red iron oxides and FD&C red #3 for 10.5 mg; titanium dioxide for all strengths.
Capsules are designed for oral administration once daily.
Packaged in blister packs or bottles for outpatient dispensing.
Stored at room temperature, protected from moisture and excessive heat.
Manufactured under stringent regulatory standards by Intra-Cellular Therapies, Inc.
Available through commercial prescription channels with insurance coverage and savings programs.
Not available in liquid or injectable forms as of current approved formulations.
Capsules appear as colored gelatin capsules consistent with specified colorants for dose identification.
Received FDA approval for schizophrenia and bipolar depression indications in adult patients.
Patient guides and medication information leaflets included with dispensed packages.
Specialty pharmacy dispensing may be required in some healthcare settings.